X 討論Moderna nearly tripled after a Phase 3 win with Merck on a personalized mRNA melanoma vaccine, then gave back more than 20% of the gain. Traders are now fighting over whether the oncology platform re-rate is real or whether the squeeze already overshot peak-sales math ahead of an expected capital raise and October ESMO detail.
多頭The Phase 3 hit validates Moderna's oncology platform beyond COVID and expands the Keytruda combo story into lung and kidney. Phase 2 ITT hazard ratio was 0.56 with distant metastasis-free survival at 0.34, and full curves at ESMO are expected to surprise skeptics.
空頭The move was a non-fundamental biotech squeeze that reverse once peak-sales math is applied, and Moderna still needs to raise equity. Even best-case melanoma economics fail to support the new valuation, with shorts covering toward double-digit prices and detailed hazard-ratio data still unpublished until ESMO.
貼文
多頭論據
@bioinvestor24Phase 2 hazard ratios show real benefit; kidney and lung should replicate, and ESMO data will surprise
@dshahhBull case: only AIxBio name with large human efficacy data and compounding oncology/infectious-disease angles; bulls winning
空頭論據
@seedy19tronShort Moderna in size: squeeze isn't fundamental, valuation can't support peak sales, and a needed equity raise is coming
@RawBooty2Headline hype misread a narrow adjuvant melanoma win as a cancer cure; limited TAM means price bleeds as visibility decays
@OverboughtWatchA 170%+ surge and ~$40B market-cap add on a small TAM drug that needs a raise is not a buy near $160
中立觀點
@DueDoctorNo ATM raise at these levels is wild — either the story is strong enough to wait or something is off